If authorised, molnupiravir could be the first oral antiviral medicine for Covid-19. Merck (known as MSD outside the United States and Canada) and Ridgeback Biotherapeutics have announced that molnupiravir, an investigational oral antiviral medicine, significantly reduced the risk of hospitalisation or death at a planned interim analysis of the Phase III MOVe-OUT trial in at […]
Menu ≡ ╳ 
